Skip to main content
TipRanks
Go Ultimate75% OFF

Stephen Squinto Insider Profile

4 Followers

Stephen Squinto, Director at Compass Therapeutics, holds ― shares in Compass Therapeutics (Ticker: CMPX), holds 6.32M shares in Springworks Therapeutics (Ticker: SWTX), holds 106.51K shares in Alexion Pharmaceuticals (Ticker: ALXN).

Stephen Squinto's Trading History

SWTX
Springworks Therapeutics
May 20, 2022―Uninformative Buy―$296.88M
ALXN
Alexion Pharmaceuticals
Oct 28, 2014―Uninformative Sell1.11M$19.44M
PASG
Passage Bio
―Head of Research and Dev, Director――
CMMB
Chemomab Therapeutics
―Director―$73.35K
CMPX
Compass Therapeutics
―Director――

You May Also Like

Stephen Squinto insider profile FAQ

What is the percentage of profitable transactions made by Stephen Squinto?
The percentage of profitable transactions made by Stephen Squinto is 33%.
What is the average return per transaction made by Stephen Squinto?
The average return per transaction made by Stephen Squinto is 7.80%.
What stocks does Stephen Squinto hold?
Stephen Squinto holds: CMPX, ALXN, CMMB, SWTX, PASG stocks.
What was Stephen Squinto's most profitable transaction?
Stephen Squinto’s most profitable transaction was an Informative Buy of SWTX stock on September 19, 2019. The return on the trade was 96.70%.
What is Stephen Squinto's role in Compass Therapeutics?
Stephen Squinto's role in Compass Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.